Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0294731 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Abhirami K Iyer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Washington University School of Medicine, St. Louis, Missouri, United States of America. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, University of Missouri-St. Louis, NINDS.
Abstract (Originalsprache)
Astrocyte-specific ion pump α2-Na + /K + -ATPase plays a critical role in the pathogenesis of amyotrophic lateral sclerosis (ALS). Here, we test the effect of Atp1a2 mRNA-specific antisense oligonucleotides (ASOs) to induce α2-Na + /K + -ATPase knockdown in the widely used ALS animal model, SOD1*G93A mice. Two ASOs led to efficient Atp1a2 knockdown and significantly reduced SOD1 aggregation in vivo . Although Atp1a2 ASO-treated mice displayed no off-target or systemic toxicity, the ASO-treated mice exhibited an accelerated disease onset and shorter lifespan than control mice. Transcriptomics studies reveal downregulation of genes involved in oxidative response, metabolic pathways, trans-synaptic signaling, and upregulation of genes involved in glutamate receptor signaling and complement activation, suggesting a potential role for these molecular pathways in de-coupling SOD1 aggregation from survival in Atp1a2 ASO-treated mice. Together, these results reveal a role for α2-Na + /K + -ATPase in SOD1 aggregation and highlight the critical effect of temporal modulation of genetically validated therapeutic targets in neurodegenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Washington University School of Medicine, St. Louis, Missouri, United States of America.
- Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, United States of America.
- Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
- Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, Missouri, United States of America.
- Neuroscience and Rare Diseases, Roche Pharma Research and Early Development (pRED), Roche Innovation Centre Basel, Basel, Switzerland.
ORCID-Profile: Abhirami K Iyer, Celeste M Karch, Azad Bonni
Förderung
- NINDS NIH HHS
- University of Missouri-St. Louis
- NINDS
- Hope Center for Neurological Disorders and the Washington University
Zitieren
APA
Iyer, A. K., Schoch, K. M., Verbeck, A., Galasso, G., Chen, H., Smith, S., Oldenborg, A., Miller, T. M., Karch, C. M., & Bonni, A. (2023). Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0294731
Vancouver
Iyer AK, Schoch KM, Verbeck A, Galasso G, Chen H, Smith S, et al. Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice. PLOS ONE. 2023. doi:10.1371/journal.pone.0294731
BibTeX
@article{Iyer2023,
author = {Iyer, Abhirami K and Schoch, Kathleen M and Verbeck, Anthony and Galasso, Grant and Chen, Hao and Smith, Sarah and Oldenborg, Anna and Miller, Timothy M and Karch, Celeste M and Bonni, Azad},
title = {Targeted ASO-mediated Atp1a2 knockdown in astrocytes reduces SOD1 aggregation and accelerates disease onset in mutant SOD1 mice},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0294731}
}
EUVIMED